Sanofi recalls painkiller in India


Indian drugmakers have often found themselves in the sights of Western regulators who have instructed them to fix plants and recall products. Now in a turnabout, one of India’s drug regulators is having Sanofi recall a painkiller it says did not meet specifications.

Sanofi has recalled four batches of Combiflam after India’s Central Drugs Standard Control Organisation (CDSCO) found it was not meeting specifications for disintegration, Reuters reports. Combiflam, a combo of paracetamol and ibuprofen, is one of the French drugmaker’s top sellers in the country, the news service reports.

A Sanofi spokeswoman told DNA India that while there was no safety issue with the drug, it was being recalled since the CDSCO had deemed it substandard. "We have acted immediately and completed the recall for two batches, while the recall of the remaining two batches is ongoing," she said, adding that the company has already taken steps to rectify the problem.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Indian drugmakers have often found their products the subjects of recalls in the U.S. Wockhardt recalled more than 7 million products last year after several of its plants came under fire by the FDA. Just this week, Indian companies Dr. Reddy’s Laboratories ($RDY) and Akorn ($AKRX) both had recalls listed by the FDA. But so did U.S. drugmakers Mylan ($MYL) and Pfizer’s ($PFE) Hospira.

- read the Reuters story 
- get more from DNA India

Related Articles: 
India's Wockhardt recalls millions of packages of drugs in sweeping recall 
Dr. Reddy's recalls drugs that failed impurities test


Suggested Articles

Roche's Perjeta is looking to build its case as an add-on treatment to standard-of-care Herceptin plus chemo in HER2-positive breast cancer patients.

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.